Laurus Labs Limited
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadershipposition in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (incl High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial…
What Laurus files
- Others45
- Investor Meet40
- Important25
- Updates23
- PPTs8
- Board Meeting7
Laurus Labs delivered a strong FY26, with revenue up 23% to ₹6,813 Cr and net profit soaring 148% to ₹889 Cr (EPS ₹16.4). The CDMO division was a key growth driver, expanding 36% and now accounts for 31% of revenue. Affordable Medicines grew 18%. The company is strategically investing in...
Laurus Labs delivered a strong financial performance for 9M FY26, with revenues soaring 30% to ₹5,001 Cr and Net Profit jumping 388% to ₹610 Cr. Q3 FY26 also saw robust growth: revenues up 26% YoY to ₹1,778 Cr, and Net Profit surging 174% YoY to ₹252 Cr. Growth was fueled...
Laurus Labs delivered a stellar H1-FY26! Revenue jumped 33% YoY to ₹3,223 Cr, while Net Profit soared 985% to ₹358 Cr. 💪 This strong performance was driven by robust CDMO growth (up 74%) and solid Generics business (up 20%), with FDF segment particularly strong at +54%. Gross margins expanded to...
Laurus Labs delivered a strong Q1 FY26, with revenue up 31% YoY to ₹ 1,570 Cr. Net Profit soared 1154% YoY to ₹ 163 Cr, driven by robust CDMO performance which grew 130% YoY in the quarter. Gross margins hit 59.4% on a favorable product mix. The company's diversification strategy...
**Financial Highlights:** Laurus Labs reported strong Q1 FY26 financial results with ₹1,570 Cr revenue, up 31% year-on-year. EBITDA surged 127% to ₹389 Cr, expanding margins by 10.5 percentage points to 24.8%. Gross margins held strong at 59.4%. The company noted continued recovery in asset turnover levels. **Strategic Initiatives & Growth...